, Singapore

Daily Markets Briefing: STI down 0.36%

Investors are predicted to still remain cautious.

The Straits Times Index (STI) ended 11.26 points or 0.36% lower to 3126.28 on Wednesday, taking the year-to-date performance to +8.52%.

The top active stocks were DBS, which declined 0.69%; Singtel, which gained 1.35%; UOB, which declined 0.28%; Keppel Corp, which declined 2.64%; and OCBC Bank, with a 0.21% fall.

OCBC Investment Research said the continued weakness on Wall Street overnight due to a lower IBM and oil prices could further dampen local bourse this morning.

Here’s more from OCBC Investment Research:

We expect investors to remain cautious amid intensifying geopolitical jitters and keep the initial hurdle at 3200. Above it, we peg the next resistance at 3250; on the downside, we peg the immediate support at 3150, ahead of 3100.

Overall volume surged 2.6% with 2.6b units traded, and total value jumped 17.8% to S$1.2b, with average value/unit hiked to 15.4% to S$0.45.
 

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare